Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

• Thomas B. Campbell ,

  * E-mail: thomas.campbell@ucdenver.edu

  Affiliation Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, United States of America

  ⨯
• Laura M. Smeaton,

  Affiliation Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• N. Kumarasamy,

  Affiliation YRG Centre for AIDS Research & Education, Chennai, India

  ⨯
• Timothy Flanigan,

  Affiliation Brown Medical School, Providence, Rhode Island, United States of America

  ⨯
• Karin L. Klingman,

  Affiliation National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Cynthia Firnhaber,

  Affiliation Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

  ⨯
• Beatriz Grinsztejn,

  Affiliation Evandro Chagas Clinical Research Institute, Fiocruz, Rio de Janeiro, Brazil

  ⨯
• Mina C. Hosseinipour,

  Affiliation Kamuzu Central Hospital, Lilongwe, Malawi

  ⨯
• Johnstone Kumwenda,

  Affiliation Department of Medicine, College of Medicine, Blantyre, Malawi

  ⨯
• Umesh Lalloo,

  Affiliation Nelson R. Mandela School of Medicine, Durban, South Africa

  ⨯
• Cynthia Riviere,

  Affiliation Institut Nacional de laboratoire et de Recherches, Port-au-Prince, Haiti

  ⨯
• Jorge Sanchez,

  Affiliation Asociación Civil Impacta Salud y Educación, Lima, Peru

  ⨯
• Marineide Melo,

  Affiliation Servico de Infectology, Hospital Nossa Senhora da Conceicao-GHC, Porto Alegre, Brazil

  ⨯
• Khuanchai Supparatpinyo,

  Affiliation Department of Medicine and Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand

  ⨯
• Srikanth Tripathy,

  Affiliation National AIDS Research Institute, Pune, India

  ⨯
• Ana I. Martinez,

  Affiliation National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Apsara Nair,

  Affiliation Frontier Science & Technology Research Foundation, Amherst, Massachusetts, United States of America

  ⨯
• Ann Walawander,

  Affiliation Frontier Science & Technology Research Foundation, Amherst, Massachusetts, United States of America

  ⨯
• Laura Moran,

  Affiliation Social & Scientific Systems, Inc, Silver Spring, Maryland, United States of America

  ⨯
• Yun Chen,

  Affiliation Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Wendy Snowden,

  Affiliation GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

  ⨯
• James F. Rooney,

  Affiliation Gilead Sciences, Inc., Foster City, California, United States of America

  ⨯
• Jonathan Uy,

  Affiliation Bristol-Myers Squibb Company, Plainsboro, New Jersey, United States of America

  ⨯
• Robert T. Schooley,

  Affiliation University of California San Diego, San Diego, United States of America

  ⨯
• Victor De Gruttola,

  Affiliation Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
•  [ ... ],
• James Gita Hakim, for the PEARLS study team of the ACTG

  Membership of the AIDS Clinical Trials Group PEARLS Team is provided in the Acknowledgments.

  Affiliation University of Zimbabwe College of Health Sciences, Harare, Zimbabwe

  ⨯
• [ view all ]
• [ view less ]